Forte Biosciences Inc (FBRX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access FBRX Annual Balance Sheets →
Examining balance sheet movements between Forte Biosciences Inc and Jun 30 2025 reveals how Jun 30 2026 adjusts its asset composition and liability profile.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent198.50
Short-term Investments, Total148.83
Cash & Short-term Investments346.00
Prepaid Expense And Other Assets Current5.07
Total Current Assets203.10
Equipment/Property/Plant Net0.24
Tax Assets, Noncurrent0.00
Other Assets, Noncurrent2.40
Total Assets205.74
Liabilities
Accounts Payable, Current AC14.01
Accrued Liabilities, Current AC6.28
Taxes Payable0.00
Total Current Liabilities20.29
Total Long-term Debt0.00
Accrued Income Taxes, Noncurrent0.00
Other liabilities, Noncurrent1.66
Total Liabilities21.95
Stockholders' Equity
Common Stock Value0.02
Additional Paid In Capital Common Stock452.67
Retained Earnings / Accumulated Deficit-268.84
Accumulated Other Comprehensive Income-0.05
Other Equity-0.05
Common Stockholder's Equity183.79
Total Stockholder's Equity183.79
Liabilities & Stockholder's Equity205.74
4 historic quarters locked

Sign in to unlock the full Forte Biosciences Inc balance sheet history.

About Forte Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-346787

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.